USA – MASSACHUSETTS Trends and Developments Contributed by: Patti Melick, Toby Bannon, Katherine Rubino and Kelsey Loomis, Wiggin and Dana LLP
Wiggin and Dana LLP 1 Federal Street, 21st Floor Boston, MA 02110 USA Tel: +1 203 498 4471 Email: dfazzio@wiggin.com Web: Wiggin.com
Later stage transactions: A shift towards certainty In contrast, later stage dealmaking increased, driven by acquiring companies seeking assets with greater clinical and regulatory clarity, spurred on by layoffs at the Food and Drug Administration (FDA) causing drug approvals to stall. M&A activity: A rebound begins After a downturn in 2023 and 2024, M&A activity in 2025 started to recover. Large pharmaceutical com- panies armed with balance sheet strength, a downturn in venture capital funding and facing patents soon to expire reignited a renewed energy to the M&A mar- kets. J.P. Morgan reported that M&A activity sur- passed 2024 to see 129 biotechnology and pharma M&A deals totalling USD138 billion. Nine transactions were above USD5 billion. Funding climate: Early signs of stabilisation Following several turbulent years marked by fundrais- ing headwinds, life science financing began to show meaningful signs of recovery. Venture investment in the biotechnology sector jumped 70.9%, rising from USD1.8 billion in Q2 2025 to USD3.1 billion in Q3 2025, an early indication that market confidence is returning. Noteworthy late stage funding included Artios Phar- ma’s USD115 million Series D round to advance its DNA damage response (DDR) oncology programmes, as well as MapLight Therapeutic’s USD372.5 million Series D to propel its pipeline targeting schizophrenia, Alzheimer’s disease, and autism spectrum disorder. Two Massachusetts based companies were high- lighted as closing significant funding rounds in 2025, including Cambridge based Be Biopharma, which
The life sciences industry experienced a year filled with signs of rebound and fresh optimism driving momen- tum forward. After several years marked by market volatility, slow deal making activity, and a pause in capital deployment, indicators of industry stabilisation emerged. The recovery has not been uniform through- out the USA, and national trends have diverged from regional hubs of innovation such as Massachusetts. Against this backdrop, this article examines some key trends and developments that emerged from the life sciences industry in 2025 throughout the USA, includ- ing certain emphasis on Massachusetts, an epicenter of biotechnology. Deal-Making National Trends Early stage transactions: Fewer deals, higher selectivity Industry reports [1 , 2 ] indicate that fewer early stage transactions closed in 2025 compared to prior years. However, the transactions that did close were focused on targeted assets. Rather than acquiring broad early stage pipelines, companies concentrated their buy- ing power on high value emerging assets with strong scientific specificity. This trend reflects a disciplined approach to risk wherein buyers were still interested in early assets but only when the asset demonstrated compelling nov- elty, validated scientific functionality, and a clear path to the clinic. These trends were reinforced by the new administration in 2025, which created uncertainty in regard to future regulatory approval processes making early stage purchases more selective and fraught with clearing a high degree of diligence. Moving forward, there may be a shift toward smaller pre-clinical deals focused on asset quality over quantity.
418 CHAMBERS.COM
Powered by FlippingBook